Yishan (Peter) Li, Ph.D., M.B.A.

Co-Founder, Head of Turning Point Therapeutics Asia

Prior to his current position, Peter served as Chairman and CEO since co-founding TP Therapeutics in October 2013 until September 2018. During these 5 years, Peter oversaw operations and financing through the company growth phases of inception, drug discovery, drug development, and clinical development with the lead compound Repotrectinib in Phase 1/2 clinical study.

Prior to founding TP Therapeutics, Peter served as Executive Vice President at Epitomics, Inc., a leading antibody technology company specializing in rabbit monoclonal antibody development for reagent, diagnostics, and therapeutics (acquired by Abcam, plc in March 2012). He spent more than 9 years at Epitomics, initially as Vice President of Life Sciences, then Senior Vice President, and Executive Vice President where he successfully built the reagent business from concept to sizable operations in both U.S. (35 FTEs) and China (165 FTEs). He oversaw all aspects of this business line, which included R&D, manufacturing, QC, marketing/sales, customer services, and oversea distributor relationship. Prior to Epitomics, Peter was Vice President at Kenson Ventures, LLC. He evaluated business plans and consulted for biotech startups on business strategies, operations, marketing and business development. He has served as members of Board of Directors and observers to the Board for multiple biotech companies.